Toxicity profile and efficacy of docetaxel following paclitaxel-or pemetrexed-platinum chemotherapy alone or in ccombination with immune checkpoint inhibitors in NSCLC patients: A single Institution experience

Background: Docetaxel alone or in combination with ramucirumab or nintedanib is recommended as second-line treatment in metastatic NSCLC after progression on first-line platinum-base chemotherapy in combination with ICIs.

The purpose of our study was to compare the toxicity profile and efficacy of docetaxel after paclitaxel- or pemetrexed-platinum chemotherapy alone or in combination with ICI.

Methods: Metastatic NSCLC patients treated with docetaxel after pemetrexed or paclitaxel-platinum with chemotherapy with or without ICI were included in our analysis.

Results: We included in our analyses a total of 53 (median age 60,3 years (SD 9,35) paclitaxel-group, and 62 years (SD 12) pemetrexed-group) patients treated at our Institution with docetaxel following either paclitaxel or pemetrexed chemotherapy. No treatment-related deaths and no new safety signals were observed.

Conclusion: Docetaxel alone or in combination with ramucirumab or nintedanib demonstrated encouraging antitumor activity with a manageable safety profile in patients who have progressed on previoous paclitaxel-or pemetrexed platinum-based chemotherapy. The results of this analysis can be a helpful reference in conducting further trials of new second-line treatment options.

Keywords: Docetaxel, pemetrexed, paclitaxel, immune checkpoint inhibitors, NSCLC

Publikationsverlauf

Artikel online veröffentlicht:
18. März 2025